Abstract
Introduction

Research on endogenous negative feedback or compensatory mechanisms that serve to limit deleterious immune responses is critical in the attempts to identify effective therapeutic targets
 [1, 2] 
. In recent years, vasoactive intestinal peptide (VIP) and VIP receptors have shown their relevance as endogenous factors that regulate inflammatory immune responses and immune tolerance
. The mechanisms involved include the deviation towards Th2-driven inflammatory pathways, the specific recruitment and development of Th2 cells and the peripheral expansion of regulatory T cells [3] . Endogenously, VIP is produced and secreted by antigen-stimulated Th2 cells [5] [6] [7] , resembling a cytokine-like acting molecule [3, 4] . Interestingly, VIP knockout mice expressed an asthmatic phenotype that is partially corrected after VIP treatment [8] . This is agreement with current views of bronchial asthma as a non-exclusive Th2 polarized immune response [9, 10] . VIP exerts its immunological actions in a paracrine and/or autocrine manner, through three different specific receptors: VIP type 1 receptor (VPAC1 ), VPAC2 and PAC1 [11, 12] . Although seminal works in the immune system described VIP as an anti-inflammatory agent, acting as an endogenous macrophage-deactivating factor (see reviews [3, 11, 13] ), very little is known about the molecular regulation of VPAC receptors in macrophages. Delgado et al. [14] have reported that in contrast to VPAC1 and PAC1 receptors -which seem to be constitutively expressed in mice macrophages -VPAC2 is selectively expressed only after lipopolysaccharide (LPS) stimulation. In lymphocytes, VPAC2 mRNA is an activation-induced gene in several experimental conditions [15] [16] [17] [18] . Despite the inducible character of the VPAC2 gene, detailed data about the promoter and regulatory elements scarcely exist and are limited to the human genome [19, 20] . Very recently, Lutz and collaborators have identified the core promoter region of the mouse VPAC2 receptor gene [21] .
The present work represents the first study of the regulation of VPAC2 mRNA by toll-like receptors (TLRs) in macrophages. TLRs are the best-characterized signal generating receptors among the pathogen-associated molecular patterns; they initiate key inflammatory responses and also shape the adaptive immunity [22, 23] . TLRs can be divided into two groups according to their cellular localization: TLRs 1, 2, 4, 5, 6 are located mainly on the cell surface and primarily recognize bacterial components, while TLRs 3, 7, 8 and 9 are mostly found in the endocytic compartments and mainly recognize viral products [22, 23] . TLR-mediated innate immune activation also induces several molecules shown to negatively regulate TLR signalling [24] . Although studies on VIP immunoregulatory activities are of notable therapeutic interest [3] 
-CCCTGGAAGGAACCAACACATAAC-3Ј (nt 1129-1152) (328 bp in length). IL-6 primers (ID genebank accession number 16193) were: forward 5Ј-TTCCATCCAGTTGCCTTCTT-3Ј, reverse 5Ј-ATTTCCACGATTTCCCAGAG-3Ј (170 bp in length spanning from nucleotide 55 to 225). SYBR-Green I detection was followed by generation of melting curves and visualization of the products to confirm specificity.
Quantitative PCR results were obtained using the ⌬⌬Ct method [25] . The induction of mRNA was calculated as 2
Ϫ⌬⌬Ct
.
Statistical significance
For statistical evaluation, Mann-Whitney rank sum tests were performed to differentiate between experimental groups.
Results and discussion
The VPAC2 gene is constitutively expressed in both Raw 264.7 cells and peritoneal macrophages (Fig. 1) . VPAC2 mRNA levels were up-regulated upon LPS treatment, as previously reported by Delgado and collaborators [14] . In our experimental setting, we were able to detect a constitutive expression of VPAC2 mRNA in resting macrophages while Delgado and collaborators [14] [39, 40] . TLR5 stimulation is mediated through the interaction with gram-positive or gram-negative bacterial flagellin [22, 24] . VPAC2 mRNA levels were not affected by treatment with this bacterial constituent (Fig. 1B) . Using peritoneal macrophages, we confirmed the pattern of VPAC2 gene regulation by TLR ligands (Fig. 1B) [24] (Fig. 2) .
TLRs have been shown to activate four major intracellular kinase signalling pathways; p38 MAPK, JNK, MEK1/2 and PI3K/Akt [24, 41, 42] (Fig. S1) . No statistically significant differences were observed in terms of cell viability compared to the control experimental situation. The proteasome inhibitor MG132 was used as a positive control for cytotoxicity.
The induction of VPAC2 expression triggered by LPS was completely abrogated by the blockade of the p38 MAPK-dependent signalling pathway with the specific inhibitor SB203580 (Fig. 3 ) [43, 44] [45] . Strikingly, SP600125 -a highly selective inhibitor of JNK activity [46] -increased the mRNA levels of VPAC2 up to 12.5 Ϯ 1.4 fold compared to control values (Fig. 3) . The cotreatment of the different TLR ligands with the specific JNK inhibitor always led to a dramatic increase in VPAC2 gene expression despite TLR2-, TLR2/6-or TLR7-mediated stimulation without a synergistic effect (Fig. 3) . Whether LPS triggers additional counter mechanisms is presently unknown, but only the LPS cotreatment with SP600125 abolished the effect that the JNK inhibitor produced by itself in Raw 264.7 cells (Fig. 3) . Addition of the MEK1/2 signalling blocker [44, 47] PD98059 led to an increase in VPAC2 mRNA levels which did not synergize with the TLR stimulation (Fig. 3) . However, LPS-induced VPAC2 expression was not reversed by blocking MEK1/2 activity, as was the case when p38 MAPK activity was inhibited (Fig. 3) , nor did LPS affect the up-regulation of VPAC2 mRNA levels by MEK1/2 inhibition as in the case of the inhibition of JNK (Fig. 3) .
. However, the up-regulation of VPAC2 mRNA levels observed after treatment with PGN (TLR2), lipoteichoic acid (TLR2/6) or imiquimod (TLR7) were not dependent on p38 MAPK activity (Fig. 3). This is the first report that ascribes a signal transduction cascade to the LPS induction of VPAC2 gene expression, although we cannot exclude a partial indirect effect mediated by pro-inflammatory cytokines triggered by LPS treatment as it has been reported in the epidermal keratinocyte cell line DJM-1 for VPAC1
We blocked PI3K/Akt activity with LY294002 [48, 49] . PI3K/Akt inhibition produced a 4.7 Ϯ 1.0 fold induction of VPAC2 mRNA in Raw 264.7 macrophages (Fig. 3) . PI3K/Akt inhibition did not reverse the TLR-mediated up-regulation of VPAC2 mRNA. Moreover, PI3K/Akt inhibition synergized with TLR ligands for TLR7, but not for TLR4, TLR2 or TLR2/6 (Fig. 3) . These data strongly suggest a tightly repressed control of VPAC2 mRNA induction by elements downstream of MEK1/2, PI3K/Akt and especially JNK signalling pathways.
Recent studies have been highlighting that VIP decreases the up-regulation of TLR2 and TLR4 in human monocytes [50] , as well as in lymphocytes, macrophages and dendritic cells after the trinitrobenzene sulfonic acid induced colitis in mice [13, 51, 52] . Interestingly, VIP has also been reported to inhibit the LPSinduced RNA expression of downstream adapters molecules involved in TLR4 signalling pathways in fibroblast-like synoviocytes from patients with rheumatoid arthritis or osteoarthritis [53] . We should notice the importance of understanding how the TLR, associated kinases pathways and VIP receptors serve to maintain the homeostasis and the integrity of the immune response. In this sense, it has been shown very recently that VIP suppresses TLR4 expression in macrophages via PI3K/Akt [54] . This is in agreement with increasing experimental evidence showing that PI3K/Akt signalling pathway has a negative regulatory role in inflammatory processes [55] [56] [57] . The VIP-mediated downregulation of the pro-inflammatory response is partly explained by activation of PKA and subsequent inhibition of p38 MAPK activity and JNK activity in macrophages [1, 3] [60] [61] [62] . Figure 4A summarizes 
